Skip to main content
Erschienen in: Diabetologia 6/2008

01.06.2008 | Review

Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

verfasst von: N. Sattar, S. G. Wannamethee, N. G. Forouhi

Erschienen in: Diabetologia | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

This review critically appraises studies examining the association of novel factors with diabetes. We show that many of the most studied novel and apparently ‘independent’ risk factors are correlated with each other by virtue of their common origins or pathways, and that residual confounding is likely. Available studies also have other limitations, including differences in methodology or inadequate statistical analyses. Furthermore, although most relevant work in this area has focused on improving our understanding of the pathogenesis of diabetes, association studies in isolation cannot prove causality; intervention studies with specific agents (if available) are required, and genetic studies may help. With respect to the potential value of novel risk factors for diabetes risk prediction, we illustrate why this work is very much in its infancy and currently not guaranteed to reach clinical utility. Indeed, the existence of several more easily measured powerful predictors of diabetes, suggests that the additional value of novel markers may be limited. Nevertheless, several suggestions to improve relevant research are given. Finally, we show that several risk factors for diabetes are only weakly associated with the risk of incident vascular events, an observation that highlights the limitations of attempting to devise unified criteria (e.g. metabolic syndrome) to identify individuals at risk of both CHD and diabetes.
Literatur
1.
Zurück zum Zitat Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef
2.
Zurück zum Zitat Sattar N, Wannamethee G, Sarwar N et al (2006) Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114:623–629PubMedCrossRef Sattar N, Wannamethee G, Sarwar N et al (2006) Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114:623–629PubMedCrossRef
3.
Zurück zum Zitat Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N (2007) Adipokines and risk of type 2 diabetes in older men. Diabetes Care 30:1200–1205PubMedCrossRef Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N (2007) Adipokines and risk of type 2 diabetes in older men. Diabetes Care 30:1200–1205PubMedCrossRef
4.
Zurück zum Zitat Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers: Results from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Diabetes Care 30:854–860PubMedCrossRef Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers: Results from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Diabetes Care 30:854–860PubMedCrossRef
5.
Zurück zum Zitat Haffner S, Temprosa M, Crandall J et al (2005) Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54:1566–1572PubMedCrossRef Haffner S, Temprosa M, Crandall J et al (2005) Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54:1566–1572PubMedCrossRef
6.
Zurück zum Zitat Haffner SM (2003) Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92:18J–26JPubMedCrossRef Haffner SM (2003) Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92:18J–26JPubMedCrossRef
7.
Zurück zum Zitat Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684PubMedCrossRef Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684PubMedCrossRef
8.
Zurück zum Zitat Hamalainen H, Ronnemaa T, Virtanen A et al (2005) Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 48:2248–2253PubMedCrossRef Hamalainen H, Ronnemaa T, Virtanen A et al (2005) Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 48:2248–2253PubMedCrossRef
9.
Zurück zum Zitat Stevens J, Couper D, Pankow J et al (2001) Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res 9:696–705PubMedCrossRef Stevens J, Couper D, Pankow J et al (2001) Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res 9:696–705PubMedCrossRef
10.
Zurück zum Zitat Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I (2007) Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev 23:551–558PubMedCrossRef Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I (2007) Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev 23:551–558PubMedCrossRef
11.
Zurück zum Zitat Norberg M, Eriksson JW, Lindahl B et al (2006) A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J Intern Med 260:263–271PubMedCrossRef Norberg M, Eriksson JW, Lindahl B et al (2006) A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J Intern Med 260:263–271PubMedCrossRef
12.
Zurück zum Zitat Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581PubMed Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581PubMed
13.
Zurück zum Zitat Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167:1068–1074PubMedCrossRef Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167:1068–1074PubMedCrossRef
14.
Zurück zum Zitat Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 16:164–171PubMedCrossRef Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 16:164–171PubMedCrossRef
15.
Zurück zum Zitat Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731PubMedCrossRef Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731PubMedCrossRef
16.
Zurück zum Zitat Schulze MB, Hoffmann K, Boeing H et al (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30:510–515PubMedCrossRef Schulze MB, Hoffmann K, Boeing H et al (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30:510–515PubMedCrossRef
17.
Zurück zum Zitat Folsom AR, Chambless LE, Ballantyne CM et al (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study. Arch Intern Med 166:1368–1373PubMedCrossRef Folsom AR, Chambless LE, Ballantyne CM et al (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study. Arch Intern Med 166:1368–1373PubMedCrossRef
18.
Zurück zum Zitat Wang TJ, Gona P, Larson MG et al (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631–2639PubMedCrossRef Wang TJ, Gona P, Larson MG et al (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631–2639PubMedCrossRef
19.
Zurück zum Zitat Hopkins TA, Ouchi N, Shibata R, Walsh K (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74:11–18PubMedCrossRef Hopkins TA, Ouchi N, Shibata R, Walsh K (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74:11–18PubMedCrossRef
20.
Zurück zum Zitat Karbowska J, Kochan Z (2006) Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J Physiol Pharmacol 57(Suppl 6):103–113PubMed Karbowska J, Kochan Z (2006) Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J Physiol Pharmacol 57(Suppl 6):103–113PubMed
21.
Zurück zum Zitat Daimon M, Oizumi T, Saitoh T et al (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata Study. Diabetes Care 26:2015–2020PubMedCrossRef Daimon M, Oizumi T, Saitoh T et al (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata Study. Diabetes Care 26:2015–2020PubMedCrossRef
22.
Zurück zum Zitat Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53:2473–2478PubMedCrossRef Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53:2473–2478PubMedCrossRef
23.
Zurück zum Zitat Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef
24.
Zurück zum Zitat Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228PubMedCrossRef Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228PubMedCrossRef
25.
Zurück zum Zitat Snijder MB, Heine RJ, Seidell JC et al (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care 29:2498–2503PubMedCrossRef Snijder MB, Heine RJ, Seidell JC et al (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care 29:2498–2503PubMedCrossRef
26.
Zurück zum Zitat Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737PubMedCrossRef Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737PubMedCrossRef
27.
Zurück zum Zitat Laughlin GA, Barrett-Connor E, May S, Langenberg C (2007) Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo Study. Am J Epidemiol 165:164–174PubMedCrossRef Laughlin GA, Barrett-Connor E, May S, Langenberg C (2007) Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo Study. Am J Epidemiol 165:164–174PubMedCrossRef
28.
Zurück zum Zitat Wannamethee SGWP, Lennon L, Sattar N (2007) Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 167:1510–1517PubMedCrossRef Wannamethee SGWP, Lennon L, Sattar N (2007) Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 167:1510–1517PubMedCrossRef
29.
Zurück zum Zitat Hara K, Horikoshi M, Yamauchi T et al (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–1362PubMedCrossRef Hara K, Horikoshi M, Yamauchi T et al (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–1362PubMedCrossRef
30.
Zurück zum Zitat McNeely MJ, Boyko EJ, Weigle DS et al (1999) Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care 22:65–70PubMedCrossRef McNeely MJ, Boyko EJ, Weigle DS et al (1999) Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care 22:65–70PubMedCrossRef
31.
Zurück zum Zitat Kanaya AM, Wassel Fyr C, Vittinghoff E et al (2006) Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 166:350–356PubMedCrossRef Kanaya AM, Wassel Fyr C, Vittinghoff E et al (2006) Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 166:350–356PubMedCrossRef
32.
Zurück zum Zitat Schmidt MI, Duncan BB, Vigo A et al (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086–2096PubMedCrossRef Schmidt MI, Duncan BB, Vigo A et al (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086–2096PubMedCrossRef
33.
Zurück zum Zitat Festa A, D’Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137PubMedCrossRef Festa A, D’Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137PubMedCrossRef
34.
Zurück zum Zitat Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113:1753–1759PubMedCrossRef Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113:1753–1759PubMedCrossRef
35.
Zurück zum Zitat Davidson M, Zhu J, Lu W et al (2006) Plasminogen activator inhibitor-1 and the risk of type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med 23:1158–1159PubMedCrossRef Davidson M, Zhu J, Lu W et al (2006) Plasminogen activator inhibitor-1 and the risk of type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med 23:1158–1159PubMedCrossRef
36.
Zurück zum Zitat Yki-Jarvinen H, Sutinen J, Silveira A et al (2003) Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 23:688–694PubMedCrossRef Yki-Jarvinen H, Sutinen J, Silveira A et al (2003) Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 23:688–694PubMedCrossRef
37.
Zurück zum Zitat Ota T, Takamura T, Kurita S et al (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132:282–293PubMedCrossRef Ota T, Takamura T, Kurita S et al (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132:282–293PubMedCrossRef
38.
Zurück zum Zitat Meigs JB, Dupuis J, Liu C et al (2006) PAI-1 gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. Obesity (Silver Spring) 14:753–758CrossRef Meigs JB, Dupuis J, Liu C et al (2006) PAI-1 gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. Obesity (Silver Spring) 14:753–758CrossRef
39.
Zurück zum Zitat Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22:437–443PubMedCrossRef Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22:437–443PubMedCrossRef
40.
Zurück zum Zitat Sattar N, Scherbakova O, Ford I et al (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:2855–2860PubMedCrossRef Sattar N, Scherbakova O, Ford I et al (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:2855–2860PubMedCrossRef
41.
Zurück zum Zitat Samuel VT, Liu ZX, Qu X et al (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345–32353PubMedCrossRef Samuel VT, Liu ZX, Qu X et al (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345–32353PubMedCrossRef
42.
Zurück zum Zitat Wannamethee SG, Shaper AG, Lennon L, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28:2913–2918PubMedCrossRef Wannamethee SG, Shaper AG, Lennon L, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28:2913–2918PubMedCrossRef
43.
Zurück zum Zitat Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA (2007) Gamma-Glutamyltransferase is associated with incident vascular events independently of alcohol intake. analysis of the British women’s heart and health study and meta-analysis. Arterioscler Thromb Vasc Biol 27:2729–2735PubMedCrossRef Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA (2007) Gamma-Glutamyltransferase is associated with incident vascular events independently of alcohol intake. analysis of the British women’s heart and health study and meta-analysis. Arterioscler Thromb Vasc Biol 27:2729–2735PubMedCrossRef
44.
Zurück zum Zitat Haffner SM (1996) Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45:233–237PubMed Haffner SM (1996) Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45:233–237PubMed
45.
Zurück zum Zitat Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288–1299PubMedCrossRef Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288–1299PubMedCrossRef
46.
Zurück zum Zitat Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291:711–717PubMedCrossRef Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291:711–717PubMedCrossRef
47.
Zurück zum Zitat Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K (1998) Relation between iron stores and non-insulin dependent diabetes in men: case–control study. BMJ 317:727PubMed Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K (1998) Relation between iron stores and non-insulin dependent diabetes in men: case–control study. BMJ 317:727PubMed
48.
Zurück zum Zitat Forouhi NG, Harding AH, Allison M et al (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50:949–956PubMedCrossRef Forouhi NG, Harding AH, Allison M et al (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50:949–956PubMedCrossRef
49.
Zurück zum Zitat Jehn ML, Guallar E, Clark JM et al (2007) A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 165:1047–1054PubMedCrossRef Jehn ML, Guallar E, Clark JM et al (2007) A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 165:1047–1054PubMedCrossRef
50.
Zurück zum Zitat Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ (2002) Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359:1740–1745PubMedCrossRef Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ (2002) Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359:1740–1745PubMedCrossRef
51.
Zurück zum Zitat Sandhu MS (2005) Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 9:44–54PubMedCrossRef Sandhu MS (2005) Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 9:44–54PubMedCrossRef
52.
Zurück zum Zitat Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM (2006) Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 114:371–376PubMedCrossRef Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM (2006) Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 114:371–376PubMedCrossRef
53.
Zurück zum Zitat Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608PubMedCrossRef Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608PubMedCrossRef
54.
Zurück zum Zitat Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755–765PubMedCrossRef Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755–765PubMedCrossRef
55.
Zurück zum Zitat Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. Diabetes 51:1596–1600PubMedCrossRef Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. Diabetes 51:1596–1600PubMedCrossRef
56.
Zurück zum Zitat Han SH, Quon MJ, Koh KK (2007) Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 18:58–65PubMedCrossRef Han SH, Quon MJ, Koh KK (2007) Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 18:58–65PubMedCrossRef
57.
Zurück zum Zitat Rask-Madsen C, King GL (2007) Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3:46–56PubMedCrossRef Rask-Madsen C, King GL (2007) Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3:46–56PubMedCrossRef
58.
Zurück zum Zitat Eliasson MC, Jansson JH, Lindahl B, Stegmayr B (2003) High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol 2:19–25PubMedCrossRef Eliasson MC, Jansson JH, Lindahl B, Stegmayr B (2003) High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol 2:19–25PubMedCrossRef
59.
Zurück zum Zitat Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 22:767–772PubMedCrossRef Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 22:767–772PubMedCrossRef
60.
Zurück zum Zitat Krakoff J, Funahashi T, Stehouwer CD et al (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751PubMedCrossRef Krakoff J, Funahashi T, Stehouwer CD et al (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751PubMedCrossRef
61.
Zurück zum Zitat Thorand B, Baumert J, Chambless L et al (2006) Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 26:398–405PubMedCrossRef Thorand B, Baumert J, Chambless L et al (2006) Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 26:398–405PubMedCrossRef
62.
Zurück zum Zitat Meigs JB, O, Donnell CJ, Tofler GH et al (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530–537PubMedCrossRef Meigs JB, O, Donnell CJ, Tofler GH et al (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530–537PubMedCrossRef
63.
Zurück zum Zitat Meigs JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291:1978–1986PubMedCrossRef Meigs JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291:1978–1986PubMedCrossRef
64.
Zurück zum Zitat Song Y, Manson JE, Tinker L et al (2007) Circulating levels of endothelial adhesion molecules and risk of diabetes mellitus in an ethnically diverse cohort of women. Diabetes 56:1898–1904PubMedCrossRef Song Y, Manson JE, Tinker L et al (2007) Circulating levels of endothelial adhesion molecules and risk of diabetes mellitus in an ethnically diverse cohort of women. Diabetes 56:1898–1904PubMedCrossRef
65.
Zurück zum Zitat Malik I, Danesh J, Whincup P et al (2001) Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358:971–976PubMedCrossRef Malik I, Danesh J, Whincup P et al (2001) Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358:971–976PubMedCrossRef
66.
67.
Zurück zum Zitat Dehghan A, Kardys I, de Maat MP et al (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56:872–878PubMedCrossRef Dehghan A, Kardys I, de Maat MP et al (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56:872–878PubMedCrossRef
68.
Zurück zum Zitat Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G (2005) Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 22:1354–1358PubMedCrossRef Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G (2005) Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 22:1354–1358PubMedCrossRef
69.
Zurück zum Zitat Lloyd-Jones DM, Liu K, Tian L, Greenland P (2006) Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 145:35–42PubMed Lloyd-Jones DM, Liu K, Tian L, Greenland P (2006) Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 145:35–42PubMed
70.
Zurück zum Zitat Sattar N, Murray HM, McConnachie A et al (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 115:981–989PubMedCrossRef Sattar N, Murray HM, McConnachie A et al (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 115:981–989PubMedCrossRef
71.
Zurück zum Zitat Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799–1805PubMedCrossRef Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799–1805PubMedCrossRef
72.
Zurück zum Zitat Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693–700PubMedCrossRef Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693–700PubMedCrossRef
73.
Zurück zum Zitat Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef
74.
Zurück zum Zitat Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812–817PubMedCrossRef Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812–817PubMedCrossRef
75.
Zurück zum Zitat Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54(Suppl 2):S114–S124PubMedCrossRef Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54(Suppl 2):S114–S124PubMedCrossRef
76.
Zurück zum Zitat Yudkin JS, Eringa E, Stehouwer CD (2005) “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365:1817–1820PubMedCrossRef Yudkin JS, Eringa E, Stehouwer CD (2005) “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365:1817–1820PubMedCrossRef
77.
Zurück zum Zitat Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214PubMedCrossRef Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214PubMedCrossRef
78.
Zurück zum Zitat Petersen AM, Pedersen BK (2006) The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57(Suppl 10):43–51PubMed Petersen AM, Pedersen BK (2006) The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57(Suppl 10):43–51PubMed
79.
Zurück zum Zitat Sargeant LA, Wareham NJ, Bingham S et al (2000) Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 23:726–732PubMedCrossRef Sargeant LA, Wareham NJ, Bingham S et al (2000) Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 23:726–732PubMedCrossRef
80.
Zurück zum Zitat Pittas AG, Lau J, Hu F, Dawson-Hughes B (2006) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92:2017–2029CrossRef Pittas AG, Lau J, Hu F, Dawson-Hughes B (2006) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92:2017–2029CrossRef
81.
Zurück zum Zitat Galloway P, McMillan DC, Sattar N (2000) Effect of the inflammatory response on trace element and vitamin status. Ann Clin Biochem 37:289–297PubMedCrossRef Galloway P, McMillan DC, Sattar N (2000) Effect of the inflammatory response on trace element and vitamin status. Ann Clin Biochem 37:289–297PubMedCrossRef
82.
Zurück zum Zitat Sattar N, McConnachie A, Ford I et al (2007) Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 56:984–991PubMedCrossRef Sattar N, McConnachie A, Ford I et al (2007) Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 56:984–991PubMedCrossRef
83.
Zurück zum Zitat Davey Smith G, Ebrahim S (2005) What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 330:1076–1079PubMedCrossRef Davey Smith G, Ebrahim S (2005) What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 330:1076–1079PubMedCrossRef
84.
Zurück zum Zitat Casas JP, Shah T, Cooper J et al (2006) Insight into the nature of the CRP—coronary event association using Mendelian randomization. Int J Epidemiol 35:922–931PubMedCrossRef Casas JP, Shah T, Cooper J et al (2006) Insight into the nature of the CRP—coronary event association using Mendelian randomization. Int J Epidemiol 35:922–931PubMedCrossRef
85.
Zurück zum Zitat Timpson NJ, Lawlor DA, Harbord RM et al (2005) C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366:1954–1959PubMedCrossRef Timpson NJ, Lawlor DA, Harbord RM et al (2005) C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366:1954–1959PubMedCrossRef
86.
Zurück zum Zitat Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-a blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86PubMed Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-a blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86PubMed
87.
Zurück zum Zitat Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56:831–839PubMedCrossRef Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56:831–839PubMedCrossRef
88.
Zurück zum Zitat Tam LS, Tomlinson B, Chu TT, Li TK, Li EK (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26:1495–1498PubMedCrossRef Tam LS, Tomlinson B, Chu TT, Li TK, Li EK (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26:1495–1498PubMedCrossRef
89.
Zurück zum Zitat Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801PubMedCrossRef Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801PubMedCrossRef
90.
Zurück zum Zitat Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRef Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRef
Metadaten
Titel
Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
verfasst von
N. Sattar
S. G. Wannamethee
N. G. Forouhi
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 6/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-0954-7

Weitere Artikel der Ausgabe 6/2008

Diabetologia 6/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.